Bispecific antibodies, which bind simultaneously to two different antigens, can attack tumors via novel mechanisms of action that cannot be evoked with combinations of conventional monoclonal ...

Bispecific ADCs represent a cutting-edge advancement, leveraging bispecific antibodies that can target two distinct antigens or epitopes, enhancing the therapeutic index of ADCs by increasing ...

Lonza’s bYlok® technology is changing the way bispecific antibodies are designed. Achieving the correct heterodimerization of light and heavy chains during bispecific production can be challenging, ...

A bispecific antibody has entered the HER2 fray with a differentiated profile from traditional agents and a chance to challenge AstraZeneca and Daiichi Sankyo’s star antibody-drug conjugate Enhertu.

This approval makes the bispecific antibody the first HER2-targeted treatment to carry the indication. Zanidatamab binds two separate regions on the HER2 cell surface protein, crosslinking ...

Recent advances in biotechnology have fuelled the development of bispecific antibodies. However, there still remains a number of development challenges for those working in bioprocessing or cell line ...

UK biotech company Kymab is to collaborate with China’s EpimAb Biotherapeutics to develop bispecific antibodies in the immuno-oncology field. Kymab has developed a next-generation antibody ...

ImmunoPrecise Antibodies, an AI-driven biotherapeutic research and technology company, has entered into a material transfer ...

The follow-on bispecific antibody ATOR-4066 is in preclinical testing. Alligator has a proprietary technology platform, comprised of two antibody libraries, ALLIGATOR-GOLD® and ALLIGATOR-FAB ...